194 patents
Page 2 of 10
Utility
HIGH PURITY gRNA SYNTHESIS PROCESS
13 Jul 23
The present disclosure relates to methods, compositions and kits for synthesizing moderate length RNAs (mlRNAs, including gRNAs) by splint-mediated ligation of RNA fragments.
Rajat Das, Ganapathy Sankaran
Filed: 23 Sep 22
Utility
Methods and compositions for treating cancer
16 May 23
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
Filed: 23 Apr 21
Utility
Genetically Engineered Immune Cells Having a Disrupted CD83 Gene
27 Apr 23
Genetically engineered immune cells such as T cells having a disrupted CD83 gene and optionally expressing a chimeric antigen receptor (CAR) and therapeutic applications thereof.
Daniel Robert Hostetter, Ismael Oumzil, Brian Christopher Fochtman, John Michael Louis Toomey
Filed: 13 Sep 22
Utility
Universal Donor Cells
27 Apr 23
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Valentin Sluch
Filed: 19 Sep 22
Utility
Gene-edited Natural Killer Cells
27 Apr 23
The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15Rα, and/or HLA-E.
Valentin SLUCH, Alireza REZANIA, Jason SAGERT
Filed: 30 Aug 22
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
11 Apr 23
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 11 May 18
Utility
Anti-idiotype Antibodies Targeting ANTI-CD19 Chimeric Antigen Receptor
6 Apr 23
High affinity antibodies capable of binding to a single-chain variable fragment (scFv) of anti-CD19 antibody FMC63, for example, the scFv expressed on cell surface as a portion of a chimeric antigen receptor (CAR).
Lalit KUMAR
Filed: 10 Feb 21
Utility
PRODRUG INCORPORATED sgRNA SYNTHESIS
6 Apr 23
Disclosed herein include guide RNA (gRNA), such as single gRNA (sgRNA), and compositions thereof, comprising 2′-O-methyldithiomethyl modified sugar moieties which can be reduced to 2′-O-methanethiol groups in the reducing environment of cells and then converted (e.g., spontaneously converted) to 2′-OH.
Rajat Das, Ganapathy Sankaran
Filed: 23 Sep 22
Utility
Compositions and Methods for Differentiating Stem Cells into NK Cells
23 Mar 23
The disclosure features methods and compositions for differentiating stem cells into hematopoietic stem and progenitor cells (HSPC) and/or Natural Killer (NK) cells.
Viktoriia KYRYCHENKO, Wai Lun LEUNG, Patrick Claudio OVANDO ROCHE
Filed: 30 Aug 22
Utility
Universal Donor Cells
9 Mar 23
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 9 Aug 22
Utility
Universal Donor Cells
9 Mar 23
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 9 Aug 22
Utility
Gene-edited natural killer cells
28 Feb 23
The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15Rα, and/or HLA-E.
Valentin Sluch, Alireza Rezania, Jason Sagert, Danielle Swain
Filed: 30 Nov 21
Utility
Characterizing Oligonucleotides
23 Feb 23
The present disclosure provides methods for determining oligonucleotide purity and/or characterizing small RNAs.
Luke J. Turechek
Filed: 19 Aug 22
Utility
Regulatable Expression Systems
16 Feb 23
Provided herein are regulatable expression systems and methods of using said regulatable expression systems to express proteins of interest.
Seshidhar Reddy Police, Kyungah Maeng
Filed: 1 Dec 20
Utility
Methods for Manufacturing Genetically Engineered Car-t Cells
16 Feb 23
Methods for manufacturing genetically engineered T cells expressing a chimeric antigen receptor (CAR), such as a CAR that binds human CD19, BCMA, or CD70, and having multiple additional gene edits, for example, a disrupted Regnase-1 gene, a disrupted TGFBRII gene, a disrupted TRAC gene, a disrupted β2M gene, or a combination thereof, using CRISPR/Cas gene editing systems.
Hui YU, Mary-Lee DEQUEANT, Demetrios KALAITZIDIS, Mohammed GHONIME
Filed: 26 Jul 22
Utility
RNA-programmable endonuclease systems and their use in genome editing and other applications
14 Feb 23
Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.
Andre Cohnen, Moritz Schmidt, Wayne Coco, Ashish Gupta, Jan Tebbe, Cindy Schulenburg, Christian Pitzler, Michael Biag Gamalinda, Sabine Jach, Florian Richter, Anup Arumughan, Corinna Saalwächter
Filed: 14 Dec 18
Utility
Universal donor cells
14 Feb 23
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Valentin Sluch
Filed: 31 Dec 21
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
9 Feb 23
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 1 Oct 21
Utility
Universal donor cells
31 Jan 23
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein.
Alireza Rezania, Valentin Sluch
Filed: 31 Dec 21
Utility
Materials and methods for treatment of friedreich ataxia and other related disorders
31 Jan 23
The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 22 Jun 17